ASND

Based on Ascendis Pharma A/S's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Ascendis Pharma do?

Ascendis Pharma is a biopharmaceutical company that develops therapies for rare and underserved conditions using its proprietary TransCon prodrug platform. Its lead commercial product, SKYTROFA, treats growth hormone deficiency in children. The pipeline extends into adult endocrine disorders, skeletal dysplasia, and oncology.

Does ASND pay dividends?

No, Ascendis Pharma does not currently pay a dividend. As a company still scaling its commercial operations and investing heavily in pipeline development, available capital is reinvested into the business rather than returned to shareholders through distributions.

When does ASND report earnings?

Ascendis Pharma reports on a quarterly cadence, as is standard for US-listed companies. For specific upcoming reporting dates and the latest financial results, check the investor relations section of the Ascendis Pharma website.

Is ASND a good stock to buy?

UQS Score rates ASND as Good overall. The Growth pillar is a standout strength, while the Quality pillar is currently Weak — reflecting the investment-heavy phase typical of commercial-stage biopharma. Whether it suits your portfolio depends on your risk tolerance and time horizon. View the full pillar breakdown on UQS Pro.

Is ASND overvalued?

The UQS Valuation pillar for ASND is rated Neutral, suggesting the market is pricing the stock in line with its fundamental profile rather than at a clear premium or discount. For the detailed valuation metrics behind this rating, a UQS Pro account provides the complete view.

How does ASND compare to its competitors?

Compared to peers like BridgeBio Pharma, Genmab, and Jazz Pharmaceuticals, Ascendis stands out through its TransCon platform — a differentiated drug-delivery technology applied across multiple rare-disease programs. Each competitor operates with a distinct therapeutic focus and commercial maturity, making direct comparisons nuanced.

What is ASND's market cap bracket?

Ascendis Pharma is classified as a large-cap company. This places it among the more established players in the specialty biopharmaceutical space, despite still being in an active commercial and pipeline growth phase.

Who founded Ascendis Pharma?

Ascendis Pharma was founded by John Fowler and Klaus Klausen, among others, and was incorporated in 2006. The company is headquartered in Hellerup, Denmark. Full founding history is publicly available through the company's official disclosures.

Is ASND a long-term quality investment?

From a long-term quality perspective, ASND's Strong Growth pillar and Good Risk rating are encouraging indicators. However, the Weak Quality pillar reflects the current profitability profile. Long-term quality potential depends on successful pipeline execution and the company's ability to scale revenue relative to its cost base.

What is the main competitive advantage of Ascendis Pharma?

Ascendis Pharma's primary competitive advantage is its TransCon platform — a proprietary prodrug technology that enables controlled, sustained release of active therapeutics. This platform is applied across multiple disease areas, creating a pipeline engine that differentiates Ascendis from companies relying on single-asset strategies.

What sector does ASND belong to?

Ascendis Pharma belongs to the [Healthcare sector](/sector/healthcare), specifically within biopharmaceuticals. The company focuses on rare and specialty diseases, a segment characterized by high unmet need, orphan drug designations, and significant R&D investment requirements.

Is ASND a growth stock or value stock?

Based on UQS pillar labels, ASND leans toward the growth category — the Growth pillar is rated Strong while the Valuation pillar is Neutral. This profile is consistent with a company where investors are pricing in future pipeline and commercial expansion rather than current earnings power.

Ascendis Pharma A/S has average quality metrics, with room for improvement in margins or capital efficiency.

Ascendis Pharma A/S is growing rapidly with strong revenue and earnings expansion.

Ascendis Pharma A/S has some risk factors including moderate leverage or solvency concerns.

Ascendis Pharma A/S has a mixed valuation — some metrics suggest fair value while others appear stretched.

Ascendis Pharma A/S possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ASND.

The UQS (Unified Quality Score) for Ascendis Pharma A/S is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Ascendis Pharma A/S's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Ascendis Pharma A/S is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.